The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Lopinavir and Ritonavir
Lopinavir and Ritonavir · LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1 · Tablet, Film Coated · Oral · Macleods Pharmaceuticals Limited
NDC 33342-0163-09 · 60 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00074-3008-60) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$4.20per unit
middle half $4.20–$4.20 · 2 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $4.20
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 100%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 8 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for lopinavir and ritonavir (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA204739
- TE code
- AB
- Approval date
- Jul 25, 2024
- Patents / exclusivity
- None on file
Shortage history
- Planned discontinuation — Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-0522-60)Jul 24, 2026
- Planned discontinuation — Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60)Jul 24, 2026
- Planned discontinuation — Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12)Jul 24, 2026
- Planned discontinuation — Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-6799-22)Jul 24, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Lopinavir and Ritonavir (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| AbbVie Deutschland GmbH & Co Kg | LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | LOPINAVIR 200 mg/1; RITONAVIR 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Laurus Labs Limited | LOPINAVIR 200 mg/1; RITONAVIR 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Laurus Labs Limited | LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | LOPINAVIR 200 mg/1; RITONAVIR 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AbbVie Deutschland GmbH & Co Kg | LOPINAVIR 200 mg/1; RITONAVIR 50 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
| AbbVie Inc. | LOPINAVIR 200 mg/1; RITONAVIR 50 mg/1 | Jul 15, 2026 | Aug 29, 2026 |
| AbbVie Inc. | LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1 | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Lopinavir and Ritonavir — NDC 33342-0163-09," retrieved September 3, 2026, https://drugdashboards.com/drug/33342016309.
Free to cite with attribution — see how the data is put together.